Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Temozolomide promotes immune escape of GBM cells via upregulating PD-L1.

Wang S, Yao F, Lu X, Li Q, Su Z, Lee JH, Wang C, Du L.

Am J Cancer Res. 2019 Jun 1;9(6):1161-1171. eCollection 2019.

2.

Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme.

Heynckes S, Daka K, Franco P, Gaebelein A, Frenking JH, Doria-Medina R, Mader I, Delev D, Schnell O, Heiland DH.

BMC Cancer. 2019 Feb 1;19(1):117. doi: 10.1186/s12885-019-5308-y.

3.

Expression differences of programmed death ligand 1 in de-novo and recurrent glioblastoma multiforme.

Heynckes S, Gaebelein A, Haaker G, Grauvogel J, Franco P, Mader I, Carro MS, Prinz M, Delev D, Schnell O, Heiland DH.

Oncotarget. 2017 Jun 28;8(43):74170-74177. doi: 10.18632/oncotarget.18819. eCollection 2017 Sep 26.

4.

Role of miR-223/paired box 6 signaling in temozolomide chemoresistance in glioblastoma multiforme cells.

Cheng Q, Ma X, Cao H, Chen Z, Wan X, Chen R, Peng R, Huang J, Jiang B.

Mol Med Rep. 2017 Feb;15(2):597-604. doi: 10.3892/mmr.2016.6078. Epub 2016 Dec 27.

5.

Snail expression contributes to temozolomide resistance in glioblastoma.

Liang H, Chen G, Li J, Yang F.

Am J Transl Res. 2019 Jul 15;11(7):4277-4289. eCollection 2019.

6.

Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition.

Liu T, Li A, Xu Y, Xin Y.

Oncol Rep. 2019 Mar;41(3):1883-1892. doi: 10.3892/or.2019.6970. Epub 2019 Jan 16.

PMID:
30664175
7.

miR-519a enhances chemosensitivity and promotes autophagy in glioblastoma by targeting STAT3/Bcl2 signaling pathway.

Li H, Chen L, Li JJ, Zhou Q, Huang A, Liu WW, Wang K, Gao L, Qi ST, Lu YT.

J Hematol Oncol. 2018 May 29;11(1):70. doi: 10.1186/s13045-018-0618-0.

8.

Preclinical Evidence of STAT3 Inhibitor Pacritinib Overcoming Temozolomide Resistance via Downregulating miR-21-Enriched Exosomes from M2 Glioblastoma-Associated Macrophages.

Chuang HY, Su YK, Liu HW, Chen CH, Chiu SC, Cho DY, Lin SZ, Chen YS, Lin CM.

J Clin Med. 2019 Jul 2;8(7). pii: E959. doi: 10.3390/jcm8070959.

9.

Tumor response of temozolomide in combination with morphine in a xenograft model of human glioblastoma.

Iorio AL, da Ros M, Genitori L, Lucchesi M, Colelli F, Signorino G, Cardile F, Laffi G, de Martino M, Pisano C, Sardi I.

Oncotarget. 2017 Aug 3;8(52):89595-89606. doi: 10.18632/oncotarget.19875. eCollection 2017 Oct 27.

10.

Effect of the STAT3 inhibitor STX-0119 on the proliferation of a temozolomide-resistant glioblastoma cell line.

Ashizawa T, Akiyama Y, Miyata H, Iizuka A, Komiyama M, Kume A, Omiya M, Sugino T, Asai A, Hayashi N, Mitsuya K, Nakasu Y, Yamaguchi K.

Int J Oncol. 2014 Jul;45(1):411-8. doi: 10.3892/ijo.2014.2439. Epub 2014 May 12.

PMID:
24820265
11.

miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.

Luo W, Yan D, Song Z, Zhu X, Liu X, Li X, Zhao S.

Life Sci. 2019 Jun 1;226:98-106. doi: 10.1016/j.lfs.2019.04.023. Epub 2019 Apr 10.

PMID:
30980849
12.

PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation.

Qiu XY, Hu DX, Chen WQ, Chen RQ, Qian SR, Li CY, Li YJ, Xiong XX, Liu D, Pan F, Yu SB, Chen XQ.

Biochim Biophys Acta Mol Basis Dis. 2018 May;1864(5 Pt A):1754-1769. doi: 10.1016/j.bbadis.2018.03.002. Epub 2018 Mar 3.

13.

Sulforaphane enhances temozolomide-induced apoptosis because of down-regulation of miR-21 via Wnt/β-catenin signaling in glioblastoma.

Lan F, Pan Q, Yu H, Yue X.

J Neurochem. 2015 Sep;134(5):811-8. doi: 10.1111/jnc.13174. Epub 2015 Jun 11.

14.

Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.

Kim SS, Rait A, Kim E, DeMarco J, Pirollo KF, Chang EH.

Cancer Lett. 2015 Dec 1;369(1):250-8. doi: 10.1016/j.canlet.2015.08.022. Epub 2015 Sep 2.

15.

FoxM1 inhibition sensitizes resistant glioblastoma cells to temozolomide by downregulating the expression of DNA-repair gene Rad51.

Zhang N, Wu X, Yang L, Xiao F, Zhang H, Zhou A, Huang Z, Huang S.

Clin Cancer Res. 2012 Nov 1;18(21):5961-71. doi: 10.1158/1078-0432.CCR-12-0039. Epub 2012 Sep 12.

16.

Effect of combined anti-PD-1 and temozolomide therapy in glioblastoma.

Park J, Kim CG, Shim JK, Kim JH, Lee H, Lee JE, Kim MH, Haam K, Jung I, Park SH, Chang JH, Shin EC, Kang SG.

Oncoimmunology. 2018 Oct 16;8(1):e1525243. doi: 10.1080/2162402X.2018.1525243. eCollection 2019.

PMID:
30546966
17.

Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.

Li Z, Zhang J, Zheng H, Li C, Xiong J, Wang W, Bao H, Jin H, Liang P.

J Exp Clin Cancer Res. 2019 Aug 28;38(1):380. doi: 10.1186/s13046-019-1371-0.

18.

Combined inhibition of vascular endothelial growth factor receptor signaling with temozolomide enhances cytotoxicity against human glioblastoma cells via downregulation of Neuropilin-1.

Lee J, Kim E, Ryu SW, Choi C, Choi K.

J Neurooncol. 2016 May;128(1):29-34. doi: 10.1007/s11060-016-2091-3. Epub 2016 Mar 7.

PMID:
26951556
19.

The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines.

Shi F, Guo H, Zhang R, Liu H, Wu L, Wu Q, Liu J, Liu T, Zhang Q.

Neuroscience. 2017 Mar 27;346:298-308. doi: 10.1016/j.neuroscience.2017.01.032. Epub 2017 Jan 29.

PMID:
28147244
20.

Valproic acid-induced amphiregulin secretion confers resistance to temozolomide treatment in human glioma cells.

Chen JC, Lee IN, Huang C, Wu YP, Chung CY, Lee MH, Lin MH, Yang JT.

BMC Cancer. 2019 Aug 1;19(1):756. doi: 10.1186/s12885-019-5843-6.

Supplemental Content

Support Center